Skip to main content

Table 3 Treatment-related adverse events

From: Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Treatment-related adverse events* Grade 1–2 Grade 3 Grade 4 Grade 5
White blood cell count decreased 18 (17.6%) 1 (1.0%) 1 (1.0%) 0
Fever 13 (12.7%) 1 (1.0%) 0 0
Anemia 11 (10.8%) 2 (2.0%) 0 0
Lymphocyte count decreased 6 (5.9%) 3 (2.9%) 1 (1.0%) 0
Neutrophil count decreased 9 (8.8%) 0 1 (1.0%) 0
Pruritus 8 (7.8%) 1 (1.0%) 0 0
Platelet count decreased 6 (5.9%) 1 (1.0%) 2 (2.0%) 0
Pneumonitis 6 (5.9%) 0 1 (1.0%) 0
Rash 4 (3.9%) 1 (1.0%) 0 0
Abnormal liver function 3 (2.9%) 2 (2.0%) 0 0
Hypertension 3 (2.9%) 1 (1.0%) 0 0
Upper respiratory tract infection 1 (1.0%) 2 (2.0%) 0 0
Infusion related reaction 2 (2.0%) 1 (1.0%) 0 0
Lung infection 0 2 (2.0%) 0 0
Febrile neutropenia 0 0 1 (1.0%) 0
Hyponatremia 0 1 (1.0%) 0 0
Abdominal infection 0 1 (1.0%) 0 0
Infection 0 2 (2.0%) 0 0
Respiratory infection 0 1 (1.0%) 0 0
Abdominal pain 0 1 (1.0%) 0 0
Allergic reaction 0 1 (1.0%) 0 0
Hyperuricemia 3 (2.9%) 0 1 (1.0%) 0
Hypokalemia 2 (2.0%) 0 1 (1.0%) 0
Heart failure 1 (1.0%) 0 1 (1.0%) 0
Autoimmune hemolytic anemia 0 0 2 (2.0%) 0
Autoimmune hepatitis 0 0 1 (1.0%) 0
Volvulus§ 0 0 0 1 (1.0%)
Death# 0 0 0 1 (1.0%)
Blood bilirubin increased 1 (1.0%) 0 1 (1.0%) 0
Reticulocyte count increased 0 1 (1.0%) 0 0
Lymphopenia 1 (1.0%) 1 (1.0%) 0 0
Weight loss 2 (2.0%) 1 (1.0%) 0 0
Bone marrow hypocellular 0 0 1 (1.0%) 0
Neutropenia 0 1 (1.0%) 0 0
  1. Data are number of patients (%). This table included all grade treatment-related adverse events occurring in at least 10% of patients and all grade 3–5 events
  2. §One patient developed volvulus during treatment and resulted in death, which was deemed uncertainly related to geptanolimab treatment by investigator
  3. #The death was deemed uncertainly related to treatment
  4. *Treatment-related adverse events were defined as an adverse event related, possibly related or uncertainly related to treatment, as assessed by the investigator
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us